Enoxacin strongly inhibited the growth of melanoma cells carrying the most common BRAF kinase oncogenic mutation V600E (Mel-Ho, A375), as well as the proliferation of cells with activating mutations in the NRAS oncogene (Mel-Juso) (Fig 1A). The gene discussed is BRAF; the disease is melanoma.